SWOG clinical trial number
CTSU/E4512

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Closed
Phase
Abbreviated Title
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK)…
Activated
08/18/2014
Closed
05/10/2024
Participants
CTSU

Research committees

Lung Cancer

Treatment

Crizotinib

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2015

ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer

DE Gerber;GR Oxnard;SJ Mandrekar;S Dahlberg;S Malik;M Mooney;J Abrams;P Janne;T Li;S Ramalingam;E Vokes;R Govindan Journal of Clinical Oncology 33:5s (suppl; abstr TPS7583); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;

ALCHEMIST trials: a golden opportunity to transform outcomes in early-stage non-small cell lung cancer

R Govindan;S Mandrekar;D Gerber;G Oxnard;S Dahlberg;J Chaft;S Malik;M Mooney;J Abrams;P Janne;D Gandara;S Ramalingam;E Vokes Clinical Cancer Research Dec 15;21(24):5439-44

PMid: PMID26672084 | PMC number: PMC4683399

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase